<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Abnormal liver biochemical tests are present in up to 30% of patients with <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> (IBD), and therefore become a diagnostic challenge </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0267792" disease_type="Disease or Syndrome" abbrv="">Liver and biliary tract diseases</z:e> are common extraintestinal manifestations for both <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> and <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> (UC), and typically do not correlate with intestinal activity </plain></SENT>
<SENT sid="2" pm="."><plain>Primary sclerosing <z:mp ids='MP_0003254'>cholangitis</z:mp> (PSC) is the most common hepatobiliary manifestation of IBD, and is more prevalent in UC </plain></SENT>
<SENT sid="3" pm="."><plain>Approximately 5% of patients with UC develop PSC, with the prevalence reaching up to 90% </plain></SENT>
<SENT sid="4" pm="."><plain><z:mpath ids='MPATH_354'>Cholangiocarcinoma</z:mpath> and <z:hpo ids='HP_0003003'>colon cancer</z:hpo> risks are increased in these patients </plain></SENT>
<SENT sid="5" pm="."><plain>Less common disorders include autoimmune <z:hpo ids='HP_0012115'>hepatitis</z:hpo>/PSC <z:e sem="disease" ids="C0410000" disease_type="Disease or Syndrome" abbrv="">overlap syndrome</z:e>, IgG4-associated cholangiopathy, primary <z:hpo ids='HP_0002613'>biliary cirrhosis</z:hpo>, hepatic <z:hpo ids='HP_0011034'>amyloidosis</z:hpo>, granulomatous <z:hpo ids='HP_0012115'>hepatitis</z:hpo>, <z:hpo ids='HP_0001081'>cholelithiasis</z:hpo>, portal vein <z:mp ids='MP_0005048'>thrombosis</z:mp>, <z:hpo ids='HP_0100523'>liver abscess</z:hpo>, and non-alcoholic <z:hpo ids='HP_0001397'>fatty liver</z:hpo> disease </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0012115'>Hepatitis</z:hpo> B reactivation during immunosuppressive therapy is a major concern, with screening and vaccination being recommended in serologically negative cases for patients with IBD </plain></SENT>
<SENT sid="7" pm="."><plain>Reactivation prophylaxis with entecavir or tenofovir for 6 to 12 mo after the end of immunosuppressive therapy is mandatory in patients showing as <z:hpo ids='HP_0012115'>hepatitis</z:hpo> B surface antigen (HBsAg) positive, independently from <z:mp ids='MP_0001799'>viral</z:mp> load </plain></SENT>
<SENT sid="8" pm="."><plain>HBsAg negative and anti-HBc positive patients, with or without anti-HBs, should be closely monitored, measuring alanine aminotransferase and <z:hpo ids='HP_0012115'>hepatitis</z:hpo> B virus DNA within 12 mo after the end of therapy, and should be treated if the <z:mp ids='MP_0001799'>viral</z:mp> load increases </plain></SENT>
<SENT sid="9" pm="."><plain>On the other hand, immunosuppressive therapy does not seem to promote reactivation of <z:hpo ids='HP_0012115'>hepatitis</z:hpo> C, and <z:hpo ids='HP_0012115'>hepatitis</z:hpo> C antiviral treatment does not influence IBD natural history either </plain></SENT>
<SENT sid="10" pm="."><plain>Most of the drugs used for IBD treatment may induce <z:e sem="disease" ids="C0235378,C0348754" disease_type="Disease or Syndrome;Injury or Poisoning" abbrv="">hepatotoxicity</z:e>, although the incidence of serious adverse events is low </plain></SENT>
<SENT sid="11" pm="."><plain>Abnormalities in liver biochemical tests associated with aminosalicylates are uncommon and are usually not clinically relevant </plain></SENT>
<SENT sid="12" pm="."><plain><z:chebi fb="0" ids="44185">Methotrexate</z:chebi>-related <z:e sem="disease" ids="C0235378,C0348754" disease_type="Disease or Syndrome;Injury or Poisoning" abbrv="">hepatotoxicity</z:e> has been described in 14% of patients with IBD, in a dose-dependent manner </plain></SENT>
<SENT sid="13" pm="."><plain>Liver biopsy is not routinely recommended </plain></SENT>
<SENT sid="14" pm="."><plain>Biologics-related <z:e sem="disease" ids="C0235378,C0348754" disease_type="Disease or Syndrome;Injury or Poisoning" abbrv="">hepatotoxicity</z:e> is rare, but has been shown most frequently in patients treated with infliximab </plain></SENT>
<SENT sid="15" pm="."><plain><z:chebi fb="0" ids="35666">Thiopurines</z:chebi> have been associated with <z:e sem="disease" ids="C0948441" disease_type="Disease or Syndrome" abbrv="VOD">veno-occlusive disease</z:e>, regenerative nodular <z:mpath ids='MPATH_134'>hyperplasia</z:mpath>, and liver <z:e sem="disease" ids="C0034150" disease_type="Disease or Syndrome" abbrv="">peliosis</z:e> </plain></SENT>
<SENT sid="16" pm="."><plain>Routine liver biochemical tests are recommended, especially during the first month of treatment </plain></SENT>
<SENT sid="17" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> these conditions should be considered in IBD patients with clinical or biochemical features suggestive of hepatobiliary involvement </plain></SENT>
<SENT sid="18" pm="."><plain>Diagnosis and management of these disorders usually involve hepatologists and gastroenterologists due to its complexity </plain></SENT>
</text></document>